You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 5,770,371


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,770,371
Title: Modification of cryptic splice sites in heterologous genes expressed in fungi
Abstract:The present invention relates to methods for obtaining a fungal host cell comprising a nucleic acid sequence encoding a heterologous polypeptide, wherein at least one cryptic splice site is modified in the nucleic acid sequence. The present invention also relates to a nucleic acid sequence(s) with a modified cryptic splice site(s) as well as nucleic acid constructs, vectors, and host cells comprising said nucleic acid sequence(s). The present invention further relates to methods for recombinant production of a polypeptide encoded by said nucleic acid sequence.
Inventor(s): Thompson; Sheryl (Davis, CA)
Assignee: Novo Nordisk Biotech, Inc. (Davis, CA)
Application Number:08/672,158
Patent Claims:1. A method for obtaining a recombinant fungal host cell, which produces a biologically active heterologous polypeptide comprising introducing into a fungal host cell a nucleic acid sequence encoding said heterologous polypeptide, wherein at least one cryptic splice site is modified in the nucleic acid sequence by replacing at least one cryptic consensus sequence of at least one cryptic splice site with a non-consensus sequence or by replacing a first region of a cryptic intron with a second region which has a percent G+C content in the range of about 40% to about 70%, wherein a recombinant fugal host cell which produces a biologically active heterologous polypeptide is obtained.

2. The method according to claim 1, wherein at least one cryptic splice site is modified by replacing a first region comprising at least one cryptic intron or portion thereof with a second region which has a percent G+C content in the range of about 40% to about 70%.

3. The method according to claim 1, wherein at least one cryptic splice site is modified both by replacing at least one cryptic consensus sequence of at least one cryptic splice site with a non-consensus sequence and by replacing a first region of a cryptic intron with a second region which has a percent G+C content in the range of about 40% to about 70%.

4. The method according to claim 1, wherein at least one cryptic splice site is modified by replacing at least one cryptic consensus sequence of at lest one cryptic splice site with a non-consensus sequence.

5. The method according to claim 4, wherein the cryptic consensus sequence is a 5' cryptic consensus sequence.

6. The method according to claim 5, wherein the 5' cryptic consensus sequence is GT, GC, or CT.

7. The method according to claim 6, wherein the 5' cryptic consensus sequence is GTANGT, GCANGT, or CTANGT, wherein N is A, C, G, or T.

8. The method according to claim 4, wherein the cryptic consensus sequence is a 3' cryptic consensus sequence.

9. The method according to claim 8, wherein the 3' cryptic consensus sequence is AG.

10. The method according to claim 8, wherein the 3' cryptic consensus sequence is CAG, TAG, or AAG.

11. The method according to claim 1, wherein the nucleic acid sequence encodes a hormone, an enzyme, a receptor, or a reporter.

12. The method according to claim 11, wherein the nucleic acid sequence encodes a reporter.

13. The method according to claim 12, wherein the reporter is an Aequorea victoria green fluorescent protein.

14. The method according to claim 1, wherein the fungal cell is a filamentous fungal cell.

15. The method according to claim 14, wherein the filamentous fungal cell is a cell of a species of Acremonium, Aspergillus, Fusarium, Humicola, Myceliophthora, Mucor, Neurospora, Penicillium, Thielavia, Tolypocladium, or Trichoderma.

16. A method for producing a biologically active polypeptide comprising

(a) introducing into a fungal host cell a nucleic acid sequence encoding said biologically active polypeptide, wherein at least one cryptic splice site is modified in the nucleic acid sequence by replacing at least one cryptic consensus sequence of at least one cryptic splice site with a non-consensus sequence or by replacing a first region of a cryptic intron with a second region which has a percent G+C content in the range of about 40% to about70%;

(b) cultivating the fungal host cell of step (a) in a nutrient medium; and

(c) recovering said biologically active polypeptide from the nutrient medium of step (b).

17. The method accordig to claim 16, in which said cryptic splice site is modified in the nucleic acid sequence by replacing at least one cryptic consensus sequence of at least one cryptic splice site with a non-consensus sequence and by replacing a first region of a cryptic intron with a second region which has a percent G+C content in the range of about 40% to about 70%.

18. An isolated nucleic acid sequence with at least one cryptic splice site modified by replacing at least one cryptic consensus sequence of at least one cryptic splice site with a non-consensus sequence and/or by replacing a first region of a cryptic intron with a second region which has a percent G+C content in the range of about 40% to about 70%, said nucleic acid sequence encoding a biologically active polypeptide.

19. A nucleic acid construct comprising the nucleic acid sequence of claim 18.

20. A recombinant fungal host cell comprising the nucleic acid construct of claim 19.

21. A recombinant expression vector comprising the nucleic acid construct of claim 19.

22. The vector according to claim 21, wherein the nucleic acid sequence is operably linked to a promoter sequence.

23. The vector according to claim 21, wherein the nucleic acid sequence is operably linked to a transcription termination signal.

24. The vector according to claim 21, further comprising a selectable marker.

25. A recombinant fungal host cell comprising the recombinant vector of claim 21.

Details for Patent 5,770,371

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.